The South Korean government said Monday it plans to tighten regulations on the misuse of medications such as Wegovy and ...

This article was reviewed by Darragh O’Carroll, MD. Ozempic Alternatives for Weight Loss Key takeaways: Ozempic® alternatives ...

Blockbuster drugs such as Ozempic have moved the dial on Chemist Warehouse sales which were 17 per cent higher through the ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. Learn more about NVO stock here.

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

Carolina Wealth Advisors, LLC added 102,629 shares of Novo Nordisk A/S, an estimated $6.01 million trade based on the average price for Q3 2025. The trade represented 2.6% of reportable AUM for the ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. A troubled Indiana ...

Novo Nordisk shares slumped Friday after President Trump said he would lower the price of the Danish company’s Ozempic drug for Americans. Speaking in the Oval Office Thursday, Trump said the cost of ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...

Novo Nordisk NOVO.B-0.54%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...